January
T2T3T4ThFrSaCN
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
February
T2T3T4ThFrSaCN
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
March
T2T3T4ThFrSaCN
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
April
T2T3T4ThFrSaCN
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
May
T2T3T4ThFrSaCN
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
June
T2T3T4ThFrSaCN
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
July
T2T3T4ThFrSaCN
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
August
T2T3T4ThFrSaCN
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
September
T2T3T4ThFrSaCN
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
October
T2T3T4ThFrSaCN
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
November
T2T3T4ThFrSaCN
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
December
T2T3T4ThFrSaCN
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
Mật độ sự kiện:
1-5
6-9
10-12
13+
Sự kiện trong 1998
—
1998: Trastuzumab (Herceptin): HER2-Targeted Therapy (1998)
Landmark Approval
Trastuzumab demonstrated that an oncogenic driver gene—present in a defined patient subset— could be pharmacologically silenced with a [[term:monoclonal-antibody|monoclonal antibody]], …
—
1998: Sildenafil: Serendipitous PDE5 Discovery (1998)
Landmark Approval
Sildenafil illustrated that rigorous attention to unexpected clinical signals during trials can salvage—and dramatically redirect—a failing programme. It created the …